Published in Neurology on June 30, 2010
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43
Multimodal classification of Alzheimer's disease and mild cognitive impairment. Neuroimage (2011) 5.24
An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol (2012) 4.36
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
Multi-modal multi-task learning for joint prediction of multiple regression and classification variables in Alzheimer's disease. Neuroimage (2011) 3.47
Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol (2012) 2.84
Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology (2012) 2.68
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2013) 2.32
Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging (2010) 2.27
Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis. CMAJ (2013) 1.82
Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease. Neurology (2011) 1.81
The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease. Am J Geriatr Psychiatry (2013) 1.80
Multi-method analysis of MRI images in early diagnostics of Alzheimer's disease. PLoS One (2011) 1.79
Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology (2012) 1.74
Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology (2013) 1.74
Random forest-based similarity measures for multi-modal classification of Alzheimer's disease. Neuroimage (2012) 1.71
Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol (2013) 1.68
Mild cognitive impairment: a concept in evolution. J Intern Med (2014) 1.65
Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid. Ann Neurol (2013) 1.63
Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology (2011) 1.63
Modeling the heterogeneity in risk of progression to Alzheimer's disease across cognitive profiles in mild cognitive impairment. Alzheimers Res Ther (2013) 1.62
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement (2011) 1.59
Apolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging. J Neurosci (2012) 1.58
Characterizing Alzheimer's disease using a hypometabolic convergence index. Neuroimage (2011) 1.54
Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci (2011) 1.51
Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol (2012) 1.44
Plasma leptin levels are not predictive of dementia in patients with mild cognitive impairment. Age Ageing (2014) 1.43
Neuroimaging Biomarkers and Impaired Olfaction in Cognitively Normal Individuals. Ann Neurol (2017) 1.39
Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.37
Neurodegenerative disease diagnosis using incomplete multi-modality data via matrix shrinkage and completion. Neuroimage (2014) 1.30
Effect of lifestyle activities on Alzheimer disease biomarkers and cognition. Ann Neurol (2012) 1.28
Accurate multimodal probabilistic prediction of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neuroimage Clin (2013) 1.25
Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. Neurology (2013) 1.13
Mild cognitive impairment: baseline and longitudinal structural MR imaging measures improve predictive prognosis. Radiology (2011) 1.13
The effects of healthy aging, amnestic mild cognitive impairment, and Alzheimer's disease on recollection and familiarity: a meta-analytic review. Neuropsychol Rev (2014) 1.12
A randomized controlled trial of multicomponent exercise in older adults with mild cognitive impairment. PLoS One (2013) 1.10
Estrogen: a master regulator of bioenergetic systems in the brain and body. Front Neuroendocrinol (2013) 1.10
Dissociable effects of Alzheimer disease and white matter hyperintensities on brain metabolism. JAMA Neurol (2013) 1.09
Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors. Alzheimers Dement (2014) 1.08
Impaired long distance functional connectivity and weighted network architecture in Alzheimer's disease. Cereb Cortex (2013) 1.07
Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med (2012) 1.07
Amyloid-β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. Brain (2015) 1.07
GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration. Nat Neurosci (2015) 1.07
Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau. Front Aging Neurosci (2013) 1.06
Subjective cognitive complaints contribute to misdiagnosis of mild cognitive impairment. J Int Neuropsychol Soc (2014) 1.04
Neuroimaging measures as endophenotypes in Alzheimer's disease. Int J Alzheimers Dis (2011) 1.04
Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers. Clin Chem (2013) 1.04
Bi-level multi-source learning for heterogeneous block-wise missing data. Neuroimage (2013) 1.02
Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative. Neurobiol Aging (2012) 1.02
Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. Neuroimage Clin (2013) 0.99
The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly. Alzheimers Dement (2013) 0.98
Alliance for aging research AD biomarkers work group: structural MRI. Neurobiol Aging (2011) 0.98
Diabetes and elevated hemoglobin A1c levels are associated with brain hypometabolism but not amyloid accumulation. J Nucl Med (2014) 0.98
Brain imaging in the study of Alzheimer's disease. Neuroimage (2011) 0.97
Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions. Alzheimers Res Ther (2010) 0.97
Relationship between baseline brain metabolism measured using [¹⁸F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease. Brain Imaging Behav (2012) 0.96
The spectrum of cognitive impairment in Lewy body diseases. Mov Disord (2014) 0.96
Quantitative structural MRI for early detection of Alzheimer's disease. Expert Rev Neurother (2010) 0.96
Genetic risk score predicting accelerated progression from mild cognitive impairment to Alzheimer's disease. J Neural Transm (Vienna) (2012) 0.95
Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction. PLoS One (2013) 0.95
Detection of early Alzheimer's disease in MCI patients by the combination of MMSE and an episodic memory test. BMC Neurol (2011) 0.94
Prediction of cognitive decline by positron emission tomography of brain amyloid and tau. Arch Neurol (2012) 0.94
Imaging biomarkers associated with cognitive decline: a review. Biol Psychiatry (2014) 0.94
Neuropsychological assessment of patients with dementing illness. Nat Rev Neurol (2011) 0.94
Manifold regularized multitask feature learning for multimodality disease classification. Hum Brain Mapp (2014) 0.93
Neuroimaging in the early diagnosis of neurodegenerative disease. Transl Neurodegener (2012) 0.91
Alzheimer's disease: implications of the updated diagnostic and research criteria. J Clin Psychiatry (2011) 0.90
Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment. PLoS One (2012) 0.90
What have novel imaging techniques revealed about metabolism in the aging brain? Future Neurol (2014) 0.89
Cardiac surgery, the brain, and inflammation. J Extra Corpor Technol (2014) 0.88
Apolipoprotein E, gender, and Alzheimer's disease: an overlooked, but potent and promising interaction. Brain Imaging Behav (2014) 0.87
Extension and refinement of the predictive value of different classes of markers in ADNI: four-year follow-up data. Alzheimers Dement (2014) 0.87
A two-study comparison of clinical and MRI markers of transition from mild cognitive impairment to Alzheimer's disease. Int J Alzheimers Dis (2012) 0.87
Meta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic Criteria. Front Aging Neurosci (2014) 0.86
Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments. Neurobiol Aging (2011) 0.86
A point-based tool to predict conversion from mild cognitive impairment to probable Alzheimer's disease. Alzheimers Dement (2014) 0.86
A focus on structural brain imaging in the Alzheimer's disease neuroimaging initiative. Biol Psychiatry (2013) 0.86
A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis. Biomed Res Int (2014) 0.85
Recent advances in imaging Alzheimer's disease. J Alzheimers Dis (2013) 0.85
Amyloid burden, neuronal function, and cognitive decline in middle-aged adults at risk for Alzheimer's disease. J Int Neuropsychol Soc (2014) 0.85
The emerging agenda of stratified medicine in neurology. Nat Rev Neurol (2013) 0.85
Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting. Eur J Nucl Med Mol Imaging (2015) 0.85
Using biomarkers to improve detection of Alzheimer's disease. Neurodegener Dis Manag (2011) 0.84
Association between an Alzheimer's Disease-Related Index and APOE ε4 Gene Dose. PLoS One (2013) 0.84
Arterial spin labeled MRI in prodromal Alzheimer's disease: A multi-site study. Neuroimage Clin (2013) 0.84
Everyday episodic memory in amnestic mild cognitive impairment: a preliminary investigation. BMC Neurosci (2011) 0.84
[11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment. Eur J Nucl Med Mol Imaging (2013) 0.83
Head trauma and in vivo measures of amyloid and neurodegeneration in a population-based study. Neurology (2013) 0.83
Thickness in entorhinal and subicular cortex predicts episodic memory decline in mild cognitive impairment. Int J Alzheimers Dis (2011) 0.83
Heterogenous mechanisms of mild cognitive impairment in Parkinson's disease. J Neural Transm (Vienna) (2011) 0.83
Mapping CSF biomarker profiles onto NIA-AA guidelines for Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci (2015) 0.83
Understanding cognitive deficits in Alzheimer's disease based on neuroimaging findings. Trends Cogn Sci (2013) 0.83
Effect of intellectual enrichment on AD biomarker trajectories: Longitudinal imaging study. Neurology (2016) 0.82
The National Institute on Aging-Alzheimer's Association research criteria for mild cognitive impairment due to Alzheimer's disease: predicting the outcome. Eur Arch Psychiatry Clin Neurosci (2012) 0.82
Simulating effects of biomarker enrichment on Alzheimer's disease prevention trials: conceptual framework and example. Alzheimers Dement (2013) 0.82
Granular expression of prolyl-peptidyl isomerase PIN1 is a constant and specific feature of Alzheimer's disease pathology and is independent of tau, Aβ and TDP-43 pathology. Acta Neuropathol (2011) 0.82
Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF. Proteomics Clin Appl (2015) 0.82
Is MRI better than CT for detecting a vascular component to dementia? A systematic review and meta-analysis. BMC Neurol (2012) 0.82
Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's Disease Neuroimaging Initiative. Neuropsychiatr Dis Treat (2014) 0.82
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
Unified segmentation. Neuroimage (2005) 30.20
An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage (2006) 25.52
A new rating scale for Alzheimer's disease. Am J Psychiatry (1984) 15.16
The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging (2008) 14.68
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol (2006) 9.99
Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology (1999) 9.86
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol (2000) 6.40
MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain (2009) 4.51
Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology (2007) 3.97
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging (2009) 3.97
Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A (2001) 3.86
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement (2007) 3.75
MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology (2009) 3.72
Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging (2003) 3.50
Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment. Arch Gen Psychiatry (2006) 3.44
Neuropsychological measures in normal individuals that predict subsequent cognitive decline. Arch Neurol (2007) 2.77
Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR Am J Neuroradiol (2010) 2.61
MRI predictors of risk of incident Alzheimer disease: a longitudinal study. Neurology (2005) 2.48
Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years. Neurology (2005) 2.45
Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment. J Neurol Neurosurg Psychiatry (2002) 2.41
Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann N Y Acad Sci (2007) 2.11
Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med (2005) 2.05
CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging (2006) 1.91
MRI and CSF studies in the early diagnosis of Alzheimer's disease. J Intern Med (2004) 1.77
Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. J Mol Neurosci (2002) 1.69
Alzheimer's disease: progress in prediction. Lancet Neurol (2010) 1.66
Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging (2007) 1.61
PENN biomarker core of the Alzheimer's disease Neuroimaging Initiative. Neurosignals (2007) 1.54
FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase (2005) 1.49
The apolipoprotein E epsilon4 allele and incident Alzheimer's disease in persons with mild cognitive impairment. Neurocase (2005) 1.49
Medial temporal atrophy but not memory deficit predicts progression to dementia in patients with mild cognitive impairment. J Neurol Neurosurg Psychiatry (2006) 1.34
Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment. Curr Alzheimer Res (2006) 1.28
Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease. J Alzheimers Dis (2009) 1.26
Rate of cognitive change in Alzheimer's disease: methodological approaches using random effects models. J Int Neuropsychol Soc (2001) 1.20
FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Res (2007) 1.18
Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature. World J Biol Psychiatry (2008) 1.17
Age and ApoE genotype interaction in Alzheimer's disease: an FDG-PET study. Psychiatry Res (2004) 0.94
The genome sequence of Drosophila melanogaster. Science (2000) 74.32
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol (1997) 10.06
Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol (2001) 9.96
Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology (1999) 9.86
Neurodegenerative tauopathies. Annu Rev Neurosci (2001) 9.53
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 9.51
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology (1997) 8.50
Second consensus statement on the diagnosis of multiple system atrophy. Neurology (2008) 7.27
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology (2009) 7.04
Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain (2008) 6.29
Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol (1997) 6.12
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol (1997) 6.02
An exploration of the sequence of a 2.9-Mb region of the genome of Drosophila melanogaster: the Adh region. Genetics (1999) 5.87
Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology (2004) 5.86
Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science (2000) 5.62
A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science (1991) 5.60
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol (1998) 5.47
Multimodal classification of Alzheimer's disease and mild cognitive impairment. Neuroimage (2011) 5.24
Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol (2003) 5.17
Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA (2001) 5.13
Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry (2001) 5.12
Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10
Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology (2005) 5.02
Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology (2000) 4.89
MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology (1992) 4.87
MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain (2009) 4.51
Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology (2002) 4.50
A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med (1995) 4.44
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39
Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 4.31
Automatic classification of patients with Alzheimer's disease from structural MRI: a comparison of ten methods using the ADNI database. Neuroimage (2010) 4.28
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol (1996) 4.10
Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline. Neuroimage (2007) 4.07
Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science (1998) 4.07
A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem (2000) 3.97
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging (2009) 3.97
Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology (1998) 3.90
Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci (2000) 3.90
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology (2000) 3.84
Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron (1997) 3.73
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology (2009) 3.72
Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer disease. Neurology (2007) 3.71
Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology (2006) 3.60
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron (1999) 3.49
Multi-modal multi-task learning for joint prediction of multiple regression and classification variables in Alzheimer's disease. Neuroimage (2011) 3.47
The short test of mental status. Correlations with standardized psychometric testing. Arch Neurol (1991) 3.45
Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron (1993) 3.45
Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology (2004) 3.41
Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage (2008) 3.40
Ethylene glycol poisoning: toxicokinetic and analytical factors affecting laboratory diagnosis. Clin Chem (1998) 3.32
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement (2010) 3.30
Epitopes that span the tau molecule are shared with paired helical filaments. Neuron (1988) 3.28
Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. Neuroimage (2010) 3.27
MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology (2007) 3.24
Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD. Neurology (2006) 3.22
Fast and robust multi-atlas segmentation of brain magnetic resonance images. Neuroimage (2009) 3.13
Anterior temporal lobes and hippocampal formations: normative volumetric measurements from MR images in young adults. Radiology (1989) 3.12
Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement (2010) 3.11
Meningitis in infancy in England and Wales: follow up at age 5 years. BMJ (2001) 3.10
Thermosensory activation of insular cortex. Nat Neurosci (2000) 3.06
Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability. Arch Neurol (2000) 3.05